{"id":"W4213247158","doi":"10.1016/s1470-2045(22)00017-1","title":"Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Merck Sharp and Dohme; National Institute for Health and Care Research; Merck; AstraZeneca","keywords":"Prostate cancer; Homologous recombination; Olaparib; Drug; Quality of life (healthcare); Hormonal therapy; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002862783,0.0001581368,0.0008145297,0.000101213,0.0002768169,0.00002264295,0.0001264714,0.00002831403,0.00002357975],"category_scores_gemma":[0.00008140466,0.00009540802,0.0000186956,0.0004151633,0.0002175257,0.0002261796,0.00004488287,0.0002749821,1.073222e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004883006,"about_ca_system_score_gemma":0.001771463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004082114,"about_ca_topic_score_gemma":0.008301661,"domain_scores_codex":[0.9963691,0.00204212,0.0006085206,0.000318489,0.0003981843,0.0002636222],"domain_scores_gemma":[0.9983331,0.0003717405,0.0006654956,0.0002716794,0.0002695632,0.0000884314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9706652,0.006356804,0.007749213,0.0001658119,0.00072714,0.00001638947,0.00325416,0.0007419382,0.003089545,0.0002598719,0.0003181814,0.006655777],"study_design_scores_gemma":[0.8950447,0.07650894,0.0242533,0.00005800952,0.0002412933,0.000003099046,0.0008244721,0.002487896,0.0002576895,0.00006966136,0.0000838487,0.0001670936],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908224,0.000544081,0.00001655069,0.003191074,0.00008285508,0.005091705,0.0001877924,0.00001807421,0.00004545159],"genre_scores_gemma":[0.9960564,0.00008767535,0.0008471166,0.0002798984,0.00006116064,0.001526685,0.001051953,0.00001944119,0.00006966885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07562047,"threshold_uncertainty_score":0.6170962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2004369039789577,"score_gpt":0.4288075307856609,"score_spread":0.2283706268067031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}